Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Cash from Financing Activities for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash from Financing Activities changed N/A year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $101.4 million (up 41.53% YoY), while the FY2025 annual figure was $101.4 million, up 41.53% from the prior year.
• Cash from Financing Activities rose to $1.3 million in Q4 2025 per INBX's latest filing, from $352000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $199.9 million in Q3 2023 and bottomed at $352000.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $53.4 million across 3 years, with a median of $32.9 million in 2024.
• On a YoY basis, Cash from Financing Activities climbed as much as 157.8% in 2025 and fell as far as 157.8% in 2025.
• Inhibrx Biosciences' Cash from Financing Activities stood at $860000.0 in 2023, then jumped by 3731.4% to $32.9 million in 2024, then tumbled by 96.19% to $1.3 million in 2025.
• Business Quant data shows INBX's Cash from Financing Activities at $1.3 million in Q4 2025, $352000.0 in Q3 2025, and $99.8 million in Q1 2025.